Aduro BioTech Inc (ADRO) Expected to Post Quarterly Sales of $4.32 Million

Wall Street brokerages expect Aduro BioTech Inc (NASDAQ:ADRO) to post sales of $4.32 million for the current fiscal quarter, Zacks reports. Four analysts have issued estimates for Aduro BioTech’s earnings. The lowest sales estimate is $3.70 million and the highest is $6.05 million. Aduro BioTech posted sales of $3.88 million during the same quarter last year, which indicates a positive year-over-year growth rate of 11.3%. The firm is expected to issue its next earnings results on Wednesday, March 7th.

According to Zacks, analysts expect that Aduro BioTech will report full year sales of $4.32 million for the current financial year, with estimates ranging from $17.19 million to $19.50 million. For the next year, analysts expect that the business will report sales of $33.03 million per share, with estimates ranging from $15.02 million to $74.82 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research analysts that follow Aduro BioTech.

Aduro BioTech (NASDAQ:ADRO) last posted its quarterly earnings data on Tuesday, October 31st. The biotechnology company reported ($0.33) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.30) by ($0.03). The firm had revenue of $3.79 million for the quarter, compared to the consensus estimate of $4.04 million. Aduro BioTech had a negative net margin of 548.92% and a negative return on equity of 39.28%. The business’s revenue was up .0% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.54) earnings per share.

A number of brokerages have recently commented on ADRO. HC Wainwright set a $18.00 price target on Aduro BioTech and gave the stock a “buy” rating in a research report on Wednesday, November 1st. Oppenheimer dropped their price target on Aduro BioTech from $15.00 to $13.00 and set an “outperform” rating on the stock in a research report on Wednesday, December 13th. BidaskClub cut Aduro BioTech from a “sell” rating to a “strong sell” rating in a research report on Wednesday, January 3rd. William Blair reissued an “outperform” rating on shares of Aduro BioTech in a research report on Monday, October 2nd. Finally, Canaccord Genuity set a $30.00 price target on Aduro BioTech and gave the stock a “buy” rating in a research report on Thursday, December 14th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have given a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $17.71.

Aduro BioTech (NASDAQ ADRO) traded up $0.40 during trading on Friday, reaching $7.30. The company’s stock had a trading volume of 637,524 shares, compared to its average volume of 513,162. The company has a market cap of $564.32 and a PE ratio of -5.37. Aduro BioTech has a fifty-two week low of $6.01 and a fifty-two week high of $14.05.

In other news, insider Stephen T. Isaacs sold 7,949 shares of the business’s stock in a transaction that occurred on Friday, January 5th. The stock was sold at an average price of $7.95, for a total value of $63,194.55. Following the sale, the insider now directly owns 213,695 shares of the company’s stock, valued at approximately $1,698,875.25. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, EVP Dirk G. Brockstedt sold 4,123 shares of the company’s stock in a transaction that occurred on Monday, November 6th. The shares were sold at an average price of $8.04, for a total value of $33,148.92. Following the completion of the transaction, the executive vice president now directly owns 77,841 shares in the company, valued at $625,841.64. The disclosure for this sale can be found here. Over the last three months, insiders sold 267,714 shares of company stock worth $2,251,452. Insiders own 6.60% of the company’s stock.

A number of hedge funds have recently added to or reduced their stakes in ADRO. Harvard Management Co. Inc. bought a new position in Aduro BioTech in the 3rd quarter valued at approximately $69,418,000. JPMorgan Chase & Co. lifted its position in Aduro BioTech by 283.7% in the 2nd quarter. JPMorgan Chase & Co. now owns 372,348 shares of the biotechnology company’s stock valued at $4,244,000 after acquiring an additional 275,295 shares in the last quarter. Nexthera Capital LP bought a new position in Aduro BioTech in the 2nd quarter valued at approximately $1,767,000. Baillie Gifford & Co. lifted its position in Aduro BioTech by 30.8% in the 3rd quarter. Baillie Gifford & Co. now owns 553,090 shares of the biotechnology company’s stock valued at $5,891,000 after acquiring an additional 130,390 shares in the last quarter. Finally, Vanguard Group Inc. lifted its position in Aduro BioTech by 5.4% in the 2nd quarter. Vanguard Group Inc. now owns 2,511,995 shares of the biotechnology company’s stock valued at $28,637,000 after acquiring an additional 129,079 shares in the last quarter. 45.19% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: This article was first reported by American Banking News and is owned by of American Banking News. If you are reading this article on another site, it was illegally stolen and reposted in violation of U.S. and international copyright legislation. The original version of this article can be viewed at https://www.americanbankingnews.com/2018/01/21/aduro-biotech-inc-adro-expected-to-post-quarterly-sales-of-4-32-million.html.

Aduro BioTech Company Profile

Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.

Get a free copy of the Zacks research report on Aduro BioTech (ADRO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Aduro BioTech (NASDAQ:ADRO)

Receive News & Ratings for Aduro BioTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro BioTech and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply